6th Australian Primary Liver Cancer Forum

23 to 25 October 2024

Perth Western Australia

A Message from the Directors

 

On behalf of the Liver Cancer Collaborative (LCC) and Gallipoli Medical Research (GMR), we are thrilled to announce the upcoming Australian Liver Cancer Forum, taking place in the vibrant city of Perth from October 23rd to 25th. The event will be held at the Harry Perkins Institute of Medical Research and attendance will be free to registered attendees.

 

This marks the first occasion, where the forum will take place outside of Queensland, symbolising a significant milestone in our collective endeavour to promote widespread collaboration to combat primary liver cancer.  We cordially invite you to join us, as we celebrate this historic milestone.

 

The 6th Australian Primary Liver Cancer Forum promises to be an enriching experience encompassing the breadth of contemporary primary liver cancer issues, including basic science, epidemiology, screening, and management, and will bring together both clinicians and basic liver cancer researchers. We aim to foster an environment conducive to the exchange of knowledge and the cultivation of collaborative initiatives.

 

Attendees will have the opportunity to listen to and network with a diverse array of national and international clinicians and scientists. Their presentations will showcase the latest advancements in primary liver cancer management and research, contributing to our collective endeavour to address this important health problem.

 

The Organising Committee are pleased to confirm the attendance of the following international speakers:

 

Professor Jonathan Fallowfield BSc (Hons), BM (Hons), PhD, MRCP

Chair of Translational Liver Research & Honorary Consultant Hepatologist, University of Edinburgh. Edinburgh, Scotland

 

Professor Peter R. Galle MD, PhD

Professor of Medicine & Director, First Department of Internal Medicine, Mainz University Medical Center. Mainz, Germany

 

Assistant Professor Daniela Sia PhD

Division of Liver Diseases, Department of Medicine, at Icahn School of Medicine at Mount Sinai. New York, USA

 

We warmly welcome you to this important event. Together, we can address the global challenge of primary liver cancer, moving towards a future marked by enhanced understanding, innovative treatments, and ultimately, improved patient outcomes.

 

Registration is free but we do require you to submit a registration form to assist with organisation of the Meeting.

 

The Organising Committee will be providing a limited number of Travel Grants to support presenting Students and Early Career Researcher authors -  so be quick to submit your abstract.

 

We look forward to welcoming you. 


Professor Peter Leedman

LCC Co-Director

Professor Nina Tirnitz-Parker

LCC Co-Director

Professor Darrell Crawford

GMRF Director of Research

Invited Speakers

  • Professor Jonathan Fallowfield BSc (Hons), BM (Hons), PhD, MRCP Chair of Translational Liver Research & Honorary Consultant Hepatologist, University of Edinburgh, Scotland

    Professor Fallowfield is a clinician scientist and Principal Investigator at the University of Edinburgh’s new Institute for Regeneration & Repair. During medical training in Southampton, he undertook a PhD on the reversibility of liver fibrosis as an MRC Clinical Research Training Fellow. He relocated to Edinburgh in 2008 as an Academy of Medical Sciences/Health Foundation Clinician Scientist Fellow. In 2014 he was awarded an NHS Research Scotland Senior Clinical Fellowship and was promoted to Personal Chair in 2018. Professor Fallowfield’s research interests span basic science to clinical trials and focus particularly on the development of new diagnostic tests and treatments for chronic liver disease and its complications. He is the clinical lead for ‘SteatoSITE’ – the world’s first data commons for NAFLD.
  • Professor Peter R. Galle MD, PhD. Professor of Medicine & Director, First Department of Internal Medicine, Mainz University Medical Centre Mainz, Germany

    Professor Galle majored in internal medicine at the Universities of Berlin, Marburg, Mannheim and Heidelberg, Germany, at Hammersmith Hospital, London/UK and, as a Fulbright grantee at University of Texas/USA and received his M.D. degree from Marburg University and Ph.D. degree from Heidelberg University.



    Initially he held a position as postdoctoral fellow in Molecular Biology at the Centre for Molecular Biology Heidelberg working on the replication of hepatitis B viruses. Afterwards he completed his residency in Internal Medicine and Gastroenterology at the University Hospital of Heidelberg. In 1998 he became Director of the I. Medical Department in Mainz and from 2005 – 2008 he holds the CEO position of Mainz University Hospital.



    He is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), served as Co-editor for the Journal of Hepatology and was on the Editorial Boards of several other Journals. He served as congress president of the German Society for Digestive Diseases (DGVS) in 2014. He was member of the Executive Board and President of the International Liver Cancer Association (ILCA). He was the President of the German Association for the Study of the Liver (GASL) for the year 2020.
  • Assistant Professor Daniela Sia PhD Division of Liver Diseases, Department of Medicine, at Icahn School of Medicine at Mount Sinai New York, USA

    Dr Sia  is an Assistant Professor in the Division of Liver Diseases, Department of Medicine, at Icahn School of Medicine at Mount Sinai. Dr. Sia is a cancer biologist with a long-standing interest in understanding the molecular basis driving hepatobiliary cancers and translating this information into more effective therapeutic strategies. During her scientific career, Dr. Sia has contributed to elucidating the genomic landscape of cholangiocarcinoma, both intrahepatic and extrahepatic, and established the first immunogenomic classification of hepatocellular carcinoma. Furthermore, she identified a novel targetable FGFR2 fusion protein, FGFR2-PPHLN1, in ~15% of intrahepatic CCA. The current goal of the Sia laboratory is to develop new treatment paradigms for clinically relevant molecular subsets of cholangiocarcinoma using genomic analyses and patient-derived and animal models. The Sia lab is supported by grants from the Department of Defense, National Cancer Institute and American Cancer Society.

Stay a little while longer and explore what Western Australia has to offer in October.

Perth

Explore Perth

Confirmed Sponsors


If you are interested in sponsoring the event please contact us at lcc@uwa.edu.au.

Bronze Sponsors

Share by: